hillevax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. our initial program, hil-214, is a virus-like particle (vlp) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
Company profile
Ticker
HLVX
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
HilleVax Securities Corporation ...
HLVX stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
12 Apr 24
S-3
Shelf registration
20 Mar 24
10-K
2023 FY
Annual report
20 Mar 24
8-K
HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress
20 Mar 24
8-K
Departure of Directors or Certain Officers
18 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Amendments to Articles of Incorporation or Bylaws
8 Dec 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
HilleVax Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
9 Nov 23
8-K
HilleVax Announces Proposed Public Offering of Common Stock
20 Sep 23
Latest ownership filings
4
James N Topper
8 Apr 24
4
Aditya Kohli
5 Apr 24
4
Sean McLoughlin
1 Apr 24
4
Aditya Kohli
20 Mar 24
144
Notice of proposed sale of securities
20 Mar 24
4
Aditya Kohli
8 Mar 24
4
Aditya Kohli
22 Feb 24
SC 13G/A
Lightspeed Venture Partners Select IV, L.P.
14 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
4
Aditya Kohli
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 210.13 mm | 210.13 mm | 210.13 mm | 210.13 mm | 210.13 mm | 210.13 mm |
Cash burn (monthly) | (no burn) | 6.96 mm | 11.30 mm | 9.68 mm | 8.94 mm | 6.97 mm |
Cash used (since last report) | n/a | 47.34 mm | 76.84 mm | 65.80 mm | 60.74 mm | 47.41 mm |
Cash remaining | n/a | 162.80 mm | 133.29 mm | 144.33 mm | 149.39 mm | 162.72 mm |
Runway (months of cash) | n/a | 23.4 | 11.8 | 14.9 | 16.7 | 23.3 |
Institutional ownership, Q2 2023
91.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 58 |
Opened positions | 5 |
Closed positions | 12 |
Increased positions | 29 |
Reduced positions | 9 |
13F shares | Current |
---|---|
Total value | 412.02 bn |
Total shares | 45.26 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Frazier Life Sciences Management | 9.78 mm | $168.14 bn |
Frazier Life Sciences Public Fund | 8.54 mm | $119.50 mm |
TAK Takeda Pharmaceutical | 6.72 mm | $0.00 |
Deerfield Management | 3.33 mm | $57.23 bn |
Flynn James E | 2.69 mm | $0.00 |
Lightspeed Venture Partners Select IV | 1.90 mm | $38.42 mm |
CG Carlyle Group Inc | 1.84 mm | $31.53 bn |
T. Rowe Price Investment Management | 1.42 mm | $24.50 mm |
BEN Franklin Resources | 1.28 mm | $22.08 bn |
BLK Blackrock | 1.27 mm | $21.84 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Apr 24 | Aditya Kohli | Common Stock | Sell | Dispose S | No | Yes | 14.44 | 6,000 | 86.64 k | 789,776 |
4 Apr 24 | Frazier Life Sciences X | Common Stock | Buy | Acquire P | No | No | 14.5 | 8,850 | 128.33 k | 8,544,187 |
4 Apr 24 | Aditya Kohli | Common Stock | Sell | Dispose S | No | Yes | 14.7075 | 6,000 | 88.25 k | 795,776 |
3 Apr 24 | Aditya Kohli | Common Stock | Sell | Dispose S | No | Yes | 14.9303 | 6,000 | 89.58 k | 801,776 |
28 Mar 24 | Sean McLoughlin | Common Stock | Buy | Acquire P | No | No | 16.98 | 1,250 | 21.23 k | 1,250 |
20 Mar 24 | Aditya Kohli | Common Stock | Sell | Dispose S | No | Yes | 164221 | 6,000 | 985.33 mm | 807,776 |
19 Mar 24 | Aditya Kohli | Common Stock | Sell | Dispose S | No | Yes | 17.4153 | 6,000 | 104.49 k | 813,776 |
18 Mar 24 | Aditya Kohli | Common Stock | Sell | Dispose S | No | Yes | 17.6561 | 6,000 | 105.94 k | 819,776 |
8 Mar 24 | Aditya Kohli | Common Stock | Sell | Dispose S | No | Yes | 18.6598 | 6,000 | 111.96 k | 825,776 |
7 Mar 24 | Aditya Kohli | Common Stock | Sell | Dispose S | No | Yes | 18.3688 | 6,000 | 110.21 k | 831,776 |